Allogeneic Transplantation to Treat Therapy Related MDS and AML in Adults. Transplant Cell Ther. 2021.
Association of CD204 macrophages with poor outcomes of malignant lymphomas not in remission treated by allo-HCT. Eur J Haematol. 2019.
Association of organ severity with mortality and recurrent malignancy in chronic graft-versus-host disease. Haematologica. 2014.
Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020.
A Case of Chronic Graft-versus-host Disease-associated Membranous Nephropathy Following Bone Marrow Transplantation, Successfully Treated with Rituximab. Intern Med. 2022..
Characterization of late acute and chronic graft-versus-host disease according to the 2014 NIH consensus criteria in Japanese patients. Biol Blood Marrow Transplant. 2018.
CIBMTR Chronic GVHD Risk Score Predicts Mortality in an Independent Validation Cohort. Biol Blood Marrow Transplant. 2014.
Comparative analysis of calcineurin-inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of Graft-versus-Host Disease after reduced intensity conditioning allogeneic transplantation. Biol Blood Marrow Transplant. 2018.
Comparison of Characteristics and Outcomes of Trial Participants and Non-participants: Example of Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial. Biol Blood Marrow Transplant. 2015.
Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups. Haematologica. 2016.
Composite GRFS and CRFS Outcomes After Adult Alternative Donor HCT. J Clin Oncol. 2020:JCO1900396.
Current status and needs of long-term follow-up clinics for hematopoietic cell transplant survivors: results of a nationwide survey in Japan. Biol Blood Marrow Transplant. 2020.
Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016.
Effect of cytomegalovirus reactivation with or without acute graft-versus-host disease on the risk of nonrelapse mortality. Clin Infect Dis. 2020.
Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016..
Extramedullary relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019..
Failure-free Survival in a Prospective Cohort of Patients with Chronic Graft-Versus-Host Disease. Haematologica. 2015.
Feasibility and usefulness of recommended screenings at long-term follow-up clinics for hematopoietic cell transplant survivors. Support Care Cancer. 2021.
Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019.
Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020.
Inferior Outcomes with Cyclosporine and Mycophenolate mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019.
Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia. Blood Adv. 2020;4(6):983-992.
Low incidence of post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation in patients with lymphoma treated with rituximab. Hematol Oncol. 2020.
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report. Transplant Cell Ther. 2021.